Aripiprazole: uses, dosing, side effects & brands

Aripiprazole is an atypical antipsychotic which is present in ABILIFY ASIMTUFII as its monohydrate polymorphic form. Aripiprazole monohydrate is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butoxy]-3,4 dihydrocarbostyril monohydrate.

The FDA classifies aripiprazole as an atypical antipsychotic. Atypical antipsychotics block dopamine D2 receptors and serotonin 5-HT2A receptors in the brain, rebalancing these signaling chemicals to reduce hallucinations, delusions, and mood symptoms in conditions like schizophrenia and bipolar disorder. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The elimination half-life of aripiprazole is about 75 hours (mean elimination half-life of the parent drug in typical adults) — that is how long the body takes to clear half of a dose. Aripiprazole has an ACTIVE metabolite, dehydro-aripiprazole, that OUTLASTS the parent: its mean elimination half-life is about 94 hours, and it represents roughly 40% of the parent drug's exposure in plasma with affinity for D2 receptors similar to the parent — so the drug's effective duration is driven by both moieties, not the ~75 h parent alone. The parent's half-life is strongly affected by CYP2D6 metabolizer status, a population the label names: in CYP2D6 poor metabolizers the mean elimination half-life is about 146 hours (roughly double). The label discusses effects of age, renal impairment, and hepatic impairment only in figures rather than as stated half-life values in the text, so no specific altered half-life numbers for those populations are quoted here. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run aripiprazole against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

We track 7 aripiprazole-containing products in the U.S.: Aripiprazole, Abilify, Abilify Asimtufii, Abilify Maintena Kit, Abilify Mycite Kit, Mezofy and Opipza. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

Across the brands we track, aripiprazole is currently marketed as solution, tablet, tablet, orally disintegrating, injectable, kit, film and soluble, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Yes. Our catalog lists 1 generic aripiprazole product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

The FDA's Enforcement database lists at least 5 recall records whose product description mentions aripiprazole. The most recent: Aripiprazole Tablets USP (May 27, 2026). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

Yes, two. First, elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death — aripiprazole is not approved for that use, and the warning applies to the whole class. Second, antidepressants and drugs used with them increase the risk of suicidal thinking and behavior in children, adolescents and young adults; aripiprazole carries this warning because it's used as an add-on for major depressive disorder. In practice that means close monitoring, especially in the first few months and after any dose change, with family or friends told what to watch for. Neither warning means the drug is wrong for you — it means the risk has to be weighed openly.

Akathisia — an internal restlessness, an inability to sit still, a driven need to pace or shift your legs. In the schizophrenia trials behind the label it occurred in 8% of patients on aripiprazole versus 4% on placebo, and in bipolar mania monotherapy trials in 13% versus 4%. It typically shows up early and is dose-related. The critical point: akathisia is routinely mistaken for worsening anxiety or agitation from the underlying condition, which leads to the dose being raised and the problem getting worse. Describe it as a physical restlessness, not as anxiety, and report it — lowering the dose or slowing the titration usually helps. The label also lists nausea, vomiting, constipation, headache, dizziness, anxiety, insomnia and restlessness among reactions occurring in 10% or more of adults.

Yes. FDA added a warning in 2016 about impulse-control problems on aripiprazole: compulsive or pathological gambling, compulsive shopping, binge eating and compulsive sexual urges. These urges can appear in people with no prior history, can start at any dose, and generally stop when the dose is lowered or the drug is discontinued. The reason this warning matters practically is that patients almost never connect the behavior to a medication — they experience it as a personal failing and hide it, sometimes after significant financial or relationship damage. Tell someone close to you to watch for it before it starts, and report any new urge of this kind immediately rather than waiting for the next appointment.

Call 911 for high fever with muscle rigidity, confusion, sweating and unstable blood pressure or heart rate — that pattern is neuroleptic malignant syndrome. Also emergency: severe rash with blistering or peeling, swelling of the face or throat, or signs of very high blood sugar and diabetic ketoacidosis (extreme thirst, frequent urination, weakness, nausea, fruity-smelling breath). Call your doctor promptly for involuntary movements of the lips, tongue, jaw or face, which may be tardive dyskinesia and can become permanent if the drug is continued; for fainting or repeated lightheadedness on standing; and for fever, sore throat or signs of infection, which can reflect a drop in white blood cells.

Aripiprazole tends to cause less weight gain and less metabolic disruption than olanzapine or quetiapine, but less is not none — weight gain, elevated blood sugar and elevated lipids all occur, and children and adolescents are more susceptible than adults. Baseline and periodic checks of weight, fasting glucose or A1c, and a lipid panel are standard. Two other practical items: aripiprazole can interfere with your body's ability to regulate temperature, so be deliberate about hydration and avoiding overheating in hot weather or hard exercise. And blood levels are affected by drugs that inhibit CYP2D6 or CYP3A4 (such as fluoxetine, paroxetine, ketoconazole) or induce them (such as carbamazepine), so dose adjustments are needed when those are started or stopped.